Literature DB >> 8083592

Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis?

H Schuitemaker1.   

Abstract

The importance of macrophage-tropic HIV-1 variants in AIDS pathogenesis becomes increasingly clear. Macrophage-tropic HIV-1 variants initiate infection, predominate in the asymptomatic phase, and persist throughout infection, even after the emergence of preferential T cell-tropic HIV-1 variants. HIV-1 infection of macrophages may contribute to the overall immune dysfunction observed in AIDS pathogenesis. Here, our knowledge of the biological variability of HIV-1, and specifically macrophage-tropic HIV-1 variants, is reviewed. Moreover, hypotheses about the mechanism of selection for macrophage-tropic variants in transmission, the mechanism by which these variants selectively persist in the asymptomatic phase, and how they may contribute to the general immune dysfunction are presented.

Entities:  

Mesh:

Year:  1994        PMID: 8083592     DOI: 10.1002/jlb.56.3.218

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Authors:  M L Penn; J C Grivel; B Schramm; M A Goldsmith; L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

2.  The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.

Authors:  Z Nie; D Bergeron; R A Subbramanian; X J Yao; F Checroune; N Rougeau; E A Cohen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.

Authors:  Adam M Spivak; Maria Salgado; S Alireza Rabi; Karen A O'Connell; Joel N Blankson
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

5.  Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.

Authors:  Gabriela Khoury; Gary Ewart; Carolyn Luscombe; Michelle Miller; John Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

6.  Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge.

Authors:  Santhi Gorantla; Kathlyn Santos; Vakara Meyer; Stephen Dewhurst; William J Bowers; Howard J Federoff; Howard E Gendelman; Larisa Poluektova
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Authors:  V Trouplin; F Salvatori; F Cappello; V Obry; A Brelot; N Heveker; M Alizon; G Scarlatti; F Clavel; F Mammano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Biol Sci       Date:  1998-11-22       Impact factor: 5.349

10.  Human immunodeficiency virus evolution towards reduced replicative fitness in vivo and the development of AIDS.

Authors:  Dominik Wodarz; David N Levy
Journal:  Proc Biol Sci       Date:  2007-10-07       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.